Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs BMS 906024 (Primary)
- Indications Acute lymphoblastic leukaemia; T cell lymphoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 28 Mar 2017 Planned End Date changed from 1 Sep 2017 to 2 Oct 2017.
- 28 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
- 27 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.